Measuring the mind: Assessing cognitive change in clinical drug trials

Expert Review of Clinical Pharmacology

Volumn 1, Issue 4, 2008, Pages 471-473

  Harrison, John ^a   Maruff, Paul ^a  

^a Scientific Division   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; CLINICAL STUDY; COGNITION; DIFFUSE LEWY BODY DISEASE; DRUG INDICATION; DRUG SAFETY; DRUG USE; EDITORIAL; EPILEPSY; HUMAN; MENTAL PERFORMANCE; MENTAL TEST; PARKINSON DISEASE; RELIABILITY; SCHIZOPHRENIA;

EID: 49449106296     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.4.471     Document Type: Editorial

References (6)

1. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426-445 (1998).
2. Falleti MG, Maruff P, Collie A, Darby D. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J. Clin. Exp. Neuropsychol. 28(7), 1095-1112 (2006).
3. Rosen WG, Mohs RC, Davies KL. A new rating scale for Alzheimer's disease. Am. J. Pschiat. 141(11), 1356-1364 (1984).
4. Committee for Medicinal Products for Human Use. Guidelines on Medicinal Products for the Treatment of Alzheimer's Disease and other Dementias. EMEA, London, UK (2007).
5. Harrison JE, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch. Neurol. 64(9), 1323-1329 (2007).
6. Ferris SH, Lucca U, Mohs R et al. Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis. Assoc. Disord. 11 (Suppl. 3), 34-38 (1997).